Erivedge 150 mg Hard gelatin capsules
PDF Leaflet Revision Date: 22 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with symptomatic metastatic and locally advanced basal cell carcinoma.
Dosage (summary)
150 mg orally once daily.
Special Populations
- Older people
- Renal impairment
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic risks.
Key Drug Interactions
- Strong CYP inducers
- P-glycoprotein inhibitors
- CYP2C9 inhibitors
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to vismodegib
- Pregnancy
- Breastfeeding
- Non-compliance with Pregnancy Prevention Programme
Common side effects
- Muscle spasms
- Alopecia
- Dysgeusia
- Weight decreased
- Fatigue
- Nausea
Counselling Points
- Use effective contraception during treatment and for 24 months after
- Notify healthcare provider of pregnancy or missed periods
- Do not donate blood or semen during and after treatment
Serious warnings
- Embryo-foetal death
- Severe birth defects
- Potential for short stature and tooth deformities in children
Important Disclaimer
The Erivedge 150 mg Hard gelatin capsules professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
